Anchor brands help Pfizer deliver Q2 earnings beat

Discussion in 'Pfizer' started by anonymous, Jul 31, 2018 at 7:14 AM.

Tags: Edit
  1. anonymous

    anonymous Guest

    Pfizer Inc. reported a rise in earnings for the second quarter, helped by the strength of its anchor brands, primarily Ibrance, Eliquis, and Xeljanz. The top and bottom lines came in above analysts’ expectations. Revenue improved by 4% driven by the continued growth of key brands, as well as biosimilars. This was partially offset by product losses of exclusivity, a decline in legacy Established Products in developed markets and ongoing legacy Hospira supply shortages. For the full year 2018, Pfizer lowered its revenue outlook while lifting its adjusted EPS guidance.

    Infographics of the company's results can be found at https://news.alphastreet.com/pfizer-q2-2018-earnings-results/
     

  2. anonymous

    anonymous Guest

    The shares fell after the company lowered its revenue outlook due to recent unfavorable change in foreign exchange rates. The stock is set to open lower on Tuesday.
     
  3. anonymous

    anonymous Guest

    Interesting that the none of the anchors are actually Pfe drugs. Pitiful.
     
  4. anonymous

    anonymous Guest

    Same old excuses and bullshit.
     
  5. anonymous

    anonymous Guest

    Where